This retrospective study examined baseline characteristics, treatment regimens, hematologic and cardiac responses, and survival outcomes in 51 patients with Mayo stage IIIb AL amyloidosis treated with daratumumab-based frontline therapy.
Specific survival rates and response data were not provided in the abstract; the study reports outcomes across hematologic response, cardiac response, and survival in 51 patients with the highest-risk AL amyloidosis stage.
Only the abstract was available for review — full outcome data, follow-up duration, and comparator details could not be assessed. Single-institution or small cohort size (n=51) may limit generalizability.
Daratumumab-based regimens are being evaluated as frontline therapy in Mayo stage IIIb AL amyloidosis, a group historically associated with very poor prognosis. Clinicians should look to the full publication for specific response rates and survival data to guide treatment decisions in this high-risk population.
Explore related topics
